DIPROLENE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIPROLENE (DIPROLENE).
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins) and inhibiting release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis.
| Metabolism | Hepatic metabolism, primarily via CYP3A4. Topical absorption is minimal but can be increased with occlusive dressings or use on large areas/damaged skin. |
| Excretion | Primarily metabolized in the liver; metabolites are excreted renally and fecally. Approximately 30-40% renally, 50-60% fecally. Biliary excretion minimal. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours for the parent drug. However, due to high potency and tissue binding, clinical effects may persist longer. Context: used for short-term management. |
| Protein binding | 99.9% bound, primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 0.35 L/kg. Represents distribution mainly into extracellular fluid with some tissue binding. |
| Bioavailability | Topical: minimal systemic absorption (approximately 1-2% with intact skin, higher with damaged skin); Intramuscular: 100%; Oral: 70-80% (first-pass metabolism). |
| Onset of Action | Topical: improvement within 3-5 days; Intramuscular: 1-2 hours; Oral: 2-4 hours. |
| Duration of Action | Topical: 1-2 days after stopping; Intramuscular: 1-2 weeks; Oral: 12-24 hours duration after single dose; clinical notes: use limited to short-term due to adverse effects. |
Topical: Apply thin film to affected area once or twice daily. Maximum dose: 45 g/week.
| Dosage form | OINTMENT, AUGMENTED |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to increased systemic absorption risk. |
| Pediatric use | Safety and efficacy not established; use only if potential benefit outweighs risk. Children ≥12 years: apply once daily; maximum 15 g/week. |
| Geriatric use | No specific adjustment; use minimal effective duration due to increased skin atrophy risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIPROLENE (DIPROLENE).
| Breastfeeding | It is unknown if betamethasone dipropionate is excreted in human milk. Systemic corticosteroids appear in breast milk in quantities not likely to affect the infant. However, caution should be exercised. M/P ratio not available. |
| Teratogenic Risk | Topical corticosteroids, including Diprolene (betamethasone dipropionate), have not been established as teratogenic in humans based on epidemiological studies. However, animal studies have shown teratogenicity with systemic corticosteroids. Risk cannot be ruled out; use only if potential benefit justifies risk. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to any component of the formulation","Untreated bacterial, fungal, viral, or parasitic infections at the treatment site"]
| Precautions | ["Systemic absorption can produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.","May increase risk of local infections; avoid use on infected lesions unless appropriate antimicrobial therapy is given.","Prolonged use may cause atrophic changes, striae, telangiectasias, or perioral dermatitis.","Use with caution on face, intertriginous areas, and in patients with impaired skin integrity."] |
Loading safety data…
| Fetal Monitoring |
| Monitor for signs of maternal adrenal suppression or Cushing's syndrome with prolonged use. Assess fetal growth if used extensively. No specific fetal monitoring required. |
| Fertility Effects | No specific studies on fertility effects. Systemic corticosteroids may impair fertility in animal studies; relevance to topical use is unknown. |